OConnell Daniel Joseph 4

What Happened

• Daniel J. O'Connell, Chief Executive Officer of Acumen Pharmaceuticals (ABOS), sold a total of 12,035 shares in two transactions to cover tax withholding related to RSU vesting. On 2026-01-21 he disposed of 9,346 shares at a weighted average price of $1.81 for proceeds of $16,927. On 2026-01-22 he disposed of 2,689 shares at a weighted average price of $1.88 for proceeds of $5,066. These were sales (routine sell-to-cover), not purchases.

Key Details

• Transaction dates and prices:
  • 2026-01-21: 9,346 shares sold, WAP $1.81, proceeds $16,927 (price range reported: $1.76–$1.88) (F2).
  • 2026-01-22: 2,689 shares sold, WAP $1.88, proceeds $5,066 (price range reported: $1.87–$1.90) (F3).
• Total shares sold: 12,035; total proceeds: ~$21,993.
• Shares owned after transaction: Not disclosed in the provided filing.
• Notable footnotes:
  • F1: Sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vesting restricted stock units, executed pursuant to a Rule 10b5-1 trading plan adopted June 24, 2024.
  • F2/F3: Reported prices are weighted-average prices; multiple trade prices within the ranges are available on request.
• Filing: Form 4 filed Jan 23, 2026 for transactions on Jan 21–22, 2026 — appears to be filed within the normal two-business-day window.

Context

• These were sell-to-cover sales tied to RSU vesting and executed under a pre-established 10b5-1 plan. Such transactions are typically for tax obligations and are generally considered routine rather than a direct signal about the CEO’s view of the stock.
• For retail investors, purchases by insiders often carry more weight as bullish signals; routine tax-related sales are common and do not necessarily indicate negative insider sentiment.